Research programme: human cytomegalovirus infections therapeutics - AiCuris

Drug Profile

Research programme: human cytomegalovirus infections therapeutics - AiCuris

Alternative Names: AIC 813; HCMV therapeutics - AiCuris

Latest Information Update: 06 Sep 2016

Price : $50

At a glance

  • Originator AiCuris
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cytomegalovirus infections

Most Recent Events

  • 06 Sep 2016 The research programme is still in preclinical development for Cytomegalovirus infections (AiCuris pipeline, September 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cytomegalovirus infections in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top